CanariaBio Inc. is a Korean biopharmaceutical company
focused on the development and commercialization of
immunotherapies for cancer.

CanariaBio's technology platform includes a portfolio of tumor
antigen specific monoclonal immunoglobulins targeting
CA-125, MUC1, PSA and Her2/neu. Since commencing patient
recruitment in October 2020, the global Phase III clinical trial for
the first-in-class flagship product 'Oregovomab', an ovarian cancer
treatment, is being conducted at 163 sites across 16 countries.